| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Treating rheumatoid arthritis to target: recommendations of an international task force.
|
Ann Rheum Dis
|
2010
|
10.97
|
|
2
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
|
Ann Rheum Dis
|
2013
|
10.92
|
|
3
|
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
|
Ann Rheum Dis
|
2010
|
10.03
|
|
4
|
Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
|
Lancet
|
2008
|
6.16
|
|
5
|
How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.
|
Arthritis Rheum
|
2002
|
5.33
|
|
6
|
Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins.
|
Arthritis Rheum
|
2005
|
5.18
|
|
7
|
Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.
|
Ann Intern Med
|
2007
|
5.05
|
|
8
|
Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.
|
Arthritis Rheum
|
2007
|
3.66
|
|
9
|
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
|
Arthritis Rheum
|
2009
|
3.58
|
|
10
|
A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions.
|
Arthritis Rheum
|
2007
|
3.23
|
|
11
|
Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues.
|
Arthritis Rheum
|
2003
|
3.05
|
|
12
|
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.
|
Ann Rheum Dis
|
2010
|
2.91
|
|
13
|
Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.
|
Arthritis Res Ther
|
2005
|
2.69
|
|
14
|
The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.
|
Arthritis Rheum
|
2006
|
2.46
|
|
15
|
Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis.
|
Arthritis Rheum
|
2004
|
2.25
|
|
16
|
Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.
|
Arthritis Rheum
|
2009
|
2.24
|
|
17
|
Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
|
Arthritis Rheum
|
2006
|
2.00
|
|
18
|
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
|
Ann Rheum Dis
|
2011
|
1.93
|
|
19
|
Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging.
|
Arthritis Rheum
|
2002
|
1.92
|
|
20
|
Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial.
|
Arthritis Rheum
|
2003
|
1.92
|
|
21
|
Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
|
Ann Rheum Dis
|
2007
|
1.77
|
|
22
|
Cell-derived microparticles in synovial fluid from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism.
|
Arthritis Rheum
|
2002
|
1.67
|
|
23
|
Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis.
|
Arthritis Rheum
|
2005
|
1.55
|
|
24
|
A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2006
|
1.50
|
|
25
|
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.
|
Ann Rheum Dis
|
2009
|
1.48
|
|
26
|
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.
|
J Rheumatol
|
2013
|
1.46
|
|
27
|
The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis.
|
Ann Rheum Dis
|
2010
|
1.39
|
|
28
|
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.
|
Ann Rheum Dis
|
2012
|
1.33
|
|
29
|
Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2005
|
1.27
|
|
30
|
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
|
J Rheumatol
|
2010
|
1.24
|
|
31
|
An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility.
|
Arthritis Rheum
|
2005
|
1.20
|
|
32
|
A randomized comparison of care provided by a clinical nurse specialist, an inpatient team, and a day patient team in rheumatoid arthritis.
|
Arthritis Rheum
|
2002
|
1.20
|
|
33
|
Effect of redox balance alterations on cellular localization of LAT and downstream T-cell receptor signaling pathways.
|
Mol Cell Biol
|
2002
|
1.17
|
|
34
|
Comparison of manual therapy and exercise therapy in osteoarthritis of the hip: a randomized clinical trial.
|
Arthritis Rheum
|
2004
|
1.15
|
|
35
|
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement.
|
Ann Rheum Dis
|
2012
|
1.13
|
|
36
|
Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial).
|
Ann Rheum Dis
|
2007
|
1.11
|
|
37
|
Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial.
|
Arthritis Rheum
|
2004
|
1.10
|
|
38
|
Two-year follow-up of a randomized controlled trial of a clinical nurse specialist intervention, inpatient, and day patient team care in rheumatoid arthritis.
|
J Adv Nurs
|
2003
|
1.08
|
|
39
|
Randomized comparison of a multidisciplinary job-retention vocational rehabilitation program with usual outpatient care in patients with chronic arthritis at risk for job loss.
|
Arthritis Rheum
|
2005
|
1.08
|
|
40
|
Criteria for early rheumatoid arthritis: from Bayes' law revisited to new thoughts on pathogenesis.
|
Arthritis Rheum
|
2002
|
1.07
|
|
41
|
Rap1 signaling is required for suppression of Ras-generated reactive oxygen species and protection against oxidative stress in T lymphocytes.
|
J Immunol
|
2004
|
1.00
|
|
42
|
An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.
|
Clin Rheumatol
|
2008
|
1.00
|
|
43
|
Association of autoantibodies to glucose-6-phosphate isomerase with extraarticular complications in rheumatoid arthritis.
|
Arthritis Rheum
|
2004
|
0.99
|
|
44
|
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
|
Ann Neurol
|
2002
|
0.99
|
|
45
|
Research in hand osteoarthritis: time for reappraisal and demand for new strategies. An opinion paper.
|
Ann Rheum Dis
|
2007
|
0.99
|
|
46
|
The need for new classification criteria for rheumatoid arthritis.
|
Arthritis Rheum
|
2005
|
0.98
|
|
47
|
Are patients with rheumatoid arthritis less physically active than the general population?
|
J Clin Rheumatol
|
2007
|
0.96
|
|
48
|
Treatment of recent-onset rheumatoid arthritis: lessons from the BeSt study.
|
J Rheumatol Suppl
|
2007
|
0.94
|
|
49
|
Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.
|
Ann Rheum Dis
|
2011
|
0.93
|
|
50
|
Leflunomide: a manageable safety profile.
|
J Rheumatol Suppl
|
2004
|
0.92
|
|
51
|
Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab.
|
Arthritis Rheum
|
2006
|
0.91
|
|
52
|
Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity.
|
Arthritis Res Ther
|
2006
|
0.91
|
|
53
|
The usage of functional wrist orthoses in patients with rheumatoid arthritis.
|
Disabil Rehabil
|
2008
|
0.89
|
|
54
|
Cost-utility and cost-effectiveness analyses of a long-term, high-intensity exercise program compared with conventional physical therapy in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2005
|
0.88
|
|
55
|
Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation.
|
Arthritis Rheum
|
2005
|
0.87
|
|
56
|
Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells.
|
Am J Pathol
|
2007
|
0.87
|
|
57
|
Controversies in COX-2 selective inhibition.
|
J Rheumatol
|
2002
|
0.86
|
|
58
|
Strong linkage on 2q33.3 to familial early-onset generalized osteoarthritis and a consideration of two positional candidate genes.
|
Eur J Hum Genet
|
2006
|
0.85
|
|
59
|
Methotrexate treatment and mortality in rheumatoid arthritis.
|
Lancet
|
2002
|
0.84
|
|
60
|
Most people with rheumatoid arthritis undertake leisure-time physical activity in the Netherlands: an observational study.
|
Aust J Physiother
|
2007
|
0.83
|
|
61
|
Innovative treatment strategies for patients with rheumatoid arthritis.
|
Curr Opin Rheumatol
|
2008
|
0.83
|
|
62
|
Changes in outcome measures for impairment, activity limitation, and participation restriction over two years in osteoarthritis of the lower extremities.
|
Arthritis Rheum
|
2008
|
0.83
|
|
63
|
The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
|
J Rheumatol Suppl
|
2004
|
0.82
|
|
64
|
Effectiveness of the introduction of an International Classification of Functioning, Disability and Health-based rehabilitation tool in multidisciplinary team care in patients with rheumatoid arthritis.
|
Arthritis Rheum
|
2007
|
0.82
|
|
65
|
Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA.
|
Curr Med Res Opin
|
2010
|
0.82
|
|
66
|
Biologics in early rheumatoid arthritis.
|
Rheum Dis Clin North Am
|
2005
|
0.79
|
|
67
|
Intranasal administration of recombinant human cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: a phase II, multicentre, double-blind, randomised, placebo-controlled, parallel-group, dose-finding trial.
|
Ann Rheum Dis
|
2009
|
0.79
|
|
68
|
High dose chemotherapy and autologous hematopoietic stem cell transplantation for rheumatoid arthritis: a review.
|
Hum Immunol
|
2002
|
0.79
|
|
69
|
Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis.
|
Rheumatology (Oxford)
|
2011
|
0.78
|
|
70
|
Linker for activation of T cells: sensing redox imbalance.
|
Methods Enzymol
|
2002
|
0.78
|
|
71
|
Brain involvement in rheumatoid arthritis: a magnetic resonance spectroscopy study.
|
Arthritis Rheum
|
2009
|
0.78
|
|
72
|
A comparison of the OARSI response criteria with patient's global assessment in patients with osteoarthritis of the hip treated with a non-pharmacological intervention.
|
Osteoarthritis Cartilage
|
2005
|
0.78
|
|
73
|
Lefunomide in combination therapy.
|
J Rheumatol Suppl
|
2004
|
0.77
|
|
74
|
Rheumatoid vasculitis treated with infliximab.
|
J Rheumatol
|
2005
|
0.76
|
|
75
|
Influence of familial factors on radiologic disease progression over two years in siblings with osteoarthritis at multiple sites: a prospective longitudinal cohort study.
|
Arthritis Rheum
|
2007
|
0.76
|
|
76
|
European rheumatology is advancing.
|
Nat Clin Pract Rheumatol
|
2006
|
0.75
|
|
77
|
InforMatrix: treatment of rheumatoid arthritis using biologicals.
|
Expert Opin Pharmacother
|
2006
|
0.75
|
|
78
|
Exercise therapy in patients with rheumatoid arthritis.
|
Curr Rheumatol Rep
|
2002
|
0.75
|